EXTENSIVE-STAGE SMALL CELL LUNG CANCER

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy and an immunotherapy drug called serplulimab. The goal is to see if this combination can delay cance…

This study tests an experimental drug called MGC018 in people with extensive-stage small-cell lung cancer that has returned or not responded to treatment. The main goal is to see if the drug can shrink tumors in at least 25% of participants. About 9 adults will receive the drug b…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with extensive-stage small cell lung cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors and to find the best dose. About 187 adults will take part in t…

This early-stage trial is testing whether adding a precise form of radiation (adaptive SBRT) to a standard immunotherapy-plus-chemotherapy regimen is safe for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. About 50 participants w…

This study tests a personalized vaccine (made from each patient's unique tumor markers) combined with the immunotherapy drug durvalumab in people with extensive-stage small cell lung cancer. The goal is to see if this combination is safe and can slow cancer growth. Only 6 partici…

This early-phase study tests a new drug called tarlatamab combined with standard chemotherapy and immunotherapy for people with extensive stage small cell lung cancer. The main goal is to check safety and side effects, while also measuring how well the tumors respond. About 184 a…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The goal is to see if the drug can shrink tumors and help control the disease. Participants receive the drug and are monitore…

This study tested whether adding low-dose radiotherapy to standard chemotherapy and an immunotherapy drug (durvalumab) could help people with extensive-stage small cell lung cancer live longer without the disease getting worse. The trial enrolled 30 adults with advanced lung canc…

This study tests a new drug, serplulimab, combined with chemotherapy for people with extensive-stage small cell lung cancer who have not had treatment before. It compares this new combination to another approved immunotherapy plus chemotherapy. The goal is to see which works bett…

This study was designed to test the safety and tolerability of a new treatment combination for people with extensive-stage small cell lung cancer who had not received prior treatment. The approach combined low-dose radiation with standard chemotherapy and two immunotherapy drugs …

This study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer. It combines a radioactive drug with standard chemotherapy and immunotherapy to see if it works better than standard care alone. About 24 adults who have not had prior t…

This study was designed to test two drugs, tarlatamab and sacituzumab govitecan, in people with advanced small cell lung cancer or a similar neuroendocrine cancer that had stopped responding to prior treatment. The goal was to see if the combination was safe and could shrink tumo…

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will take part. The main goal …

This study tests a new drug called BNT327 combined with chemotherapy in people with a hard-to-treat type of lung cancer (small-cell lung cancer). About 110 adults will take part, some getting the combo as their first treatment and others after earlier treatments stopped working. …